Xenon Pharmaceuticals Balance Sheet
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals financial position
At the end of fiscal 2025, Xenon Pharmaceuticals reported total assets of $633.2 million, down 20.7% from a year earlier against total liabilities of $51.4 million. Shareholders' equity stood at $581.8 million, or 91.9% of assets. The company held $199.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 13.42, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 199.16M | 142.71M | 148.64M | 57.24M | 175.69M | 45.01M | 24.75M | 67.75M | 20.49M | 17.09M |
| Short-Term Investments | 349.72M | 484.19M | 489.44M | 534.85M | 376.09M | 131.99M | 116.60M | 51.55M | 23.18M | 47.05M |
| Receivables | — | 1.47M | 874.00K | 986.00K | 2.77M | 1.82M | 813.00K | 151.00K | 438.00K | 200.00K |
| Total Current Assets | 560.65M | 635.26M | 644.96M | 600.30M | 559.02M | 181.78M | 144.87M | 121.33M | 44.82M | 65.67M |
| Property, Plant & Equipment | 8.72M | 10.28M | 9.65M | 6.50M | 4.47M | 3.55M | 1.66M | 991.00K | 1.07M | 1.40M |
| Long-Term Investments | 37.15M | 127.50M | 292.79M | 128.68M | 0 | — | — | — | — | — |
| Total Assets | 633.16M | 798.14M | 964.80M | 754.15M | 572.01M | 189.19M | 147.70M | 122.43M | 46.12M | 67.49M |
| Accounts Payable | 3.88M | 5.07M | 8.60M | 8.49M | 3.82M | 3.04M | 2.47M | 665.00K | 1.25M | 1.46M |
| Short-Term Debt | — | — | — | — | — | — | 4.65M | — | 700.00K | — |
| Total Current Liabilities | 41.79M | 35.59M | 27.27M | 22.70M | 14.32M | 14.78M | 43.38M | 4.12M | 4.08M | 3.59M |
| Long-Term Debt | — | — | — | — | — | — | 10.89M | 15.01M | 6.10M | — |
| Total Liabilities | 51.40M | 43.24M | 36.88M | 32.65M | 21.97M | 17.83M | 55.72M | 19.13M | 10.19M | 3.59M |
| Shareholders' Equity | 581.76M | 754.90M | 927.92M | 721.50M | 550.03M | 171.35M | 91.98M | 103.30M | 35.93M | 63.90M |
| Retained Earnings | -1.25B | -899.47M | -665.14M | -482.75M | -357.37M | -278.49M | -249.66M | -207.88M | -173.39M | -142.68M |
| Total Debt | — | — | — | — | — | — | 15.54M | 15.01M | 6.80M | — |
| Net Cash (Debt) | 548.89M | 626.90M | 638.08M | 592.09M | 551.77M | 177.00M | 125.82M | 104.29M | 36.86M | 64.15M |
| Shares Outstanding | 80.01M | 76.42M | 75.37M | 62.59M | 51.63M | 35.01M | 28.14M | 25.75M | 18.00M | 17.93M |
This table shows 10 annual periods of Xenon Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a balance sheet?